A single-center, open-label, phase II, safety, pharmacokinetic and efficacy [study] of Panzem Nanocrystal Colloidal Dispersion [2-methoxyestradiol] administered orally to patients with recurrent glioblastoma multiforme

Trial Profile

A single-center, open-label, phase II, safety, pharmacokinetic and efficacy [study] of Panzem Nanocrystal Colloidal Dispersion [2-methoxyestradiol] administered orally to patients with recurrent glioblastoma multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs 2-methoxyestradiol (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors EntreMed
  • Most Recent Events

    • 09 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 26 Apr 2008 The expected completion date for this trial is 1 Jul 2008.
    • 29 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top